News coverage about Immune Design (NASDAQ:IMDZ) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immune Design earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.6433349308605 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of brokerages have recently issued reports on IMDZ. Zacks Investment Research raised shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Tuesday. Cowen reaffirmed a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Immune Design has a consensus rating of “Buy” and a consensus target price of $13.13.

Immune Design (NASDAQ:IMDZ) traded down $0.08 on Wednesday, hitting $3.87. 209,396 shares of the company were exchanged, compared to its average volume of 542,279. The stock has a market capitalization of $194.63, a P/E ratio of -1.83 and a beta of 2.10. Immune Design has a one year low of $2.80 and a one year high of $13.05.

In other Immune Design news, CEO Carlos V. Paya sold 7,970 shares of Immune Design stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $4.17, for a total transaction of $33,234.90. Following the transaction, the chief executive officer now owns 114,560 shares of the company’s stock, valued at $477,715.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Leo Guthart purchased 20,000 shares of the stock in a transaction on Monday, January 8th. The shares were purchased at an average cost of $3.90 per share, for a total transaction of $78,000.00. The disclosure for this purchase can be found here. In the last three months, insiders sold 13,959 shares of company stock worth $58,209. 20.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Immune Design (IMDZ) Earns Daily News Impact Score of 0.16” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with's FREE daily email newsletter.